+ All Categories
Home > Documents > FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT...

FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT...

Date post: 28-Oct-2019
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
17
FIRST RESULTS OF PROJECT EMPORE-LIFE15 “DEVELOPMENT OF AN EFFICIENT AND SUSTAINABLE METHODOLOGY FOR EMERGING POLLUTANTS REMOVAL IN WWTPS” (EMPORE-LIFE15 ENV/ES/000598) Autores/Authors: M.A., Bernal-Romero del Hombre Bueno; R., González; A. Sánchez; J.M., Santos; F., Martínez; H., García; S., Oyonarte; F., Bosch; M., Company; J., Andreu; L. Mendes-Predolin; D. Prats Presentador/Presenter: Mª Ángeles Bernal Romero del Hombre Bueno (universidad de Alicante) ma.bernal @ua.es ISBN 978-84-09-04625-6
Transcript
Page 1: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

FIRST RESULTS OF PROJECT EMPORE-LIFE15 “DEVELOPMENT OF AN EFFICIENT AND SUSTAINABLE METHODOLOGY FOR EMERGING POLLUTANTS REMOVAL IN WWTPS” (EMPORE-LIFE15 ENV/ES/000598)

Autores/Authors: M.A., Bernal-Romero del Hombre Bueno; R., González; A. Sánchez; J.M., Santos; F., Martínez; H., García; S., Oyonarte; F., Bosch; M., Company; J., Andreu; L. Mendes-Predolin; D. Prats

Presentador/Presenter: Mª Ángeles Bernal Romero del Hombre Bueno (universidad de Alicante) [email protected]

ISBN 978-84-09-04625-6

Page 2: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.org

EMPORE LIFE-EMPORE aims to demonstrate an innovative, cost-efficient and highly

replicable technology for the removal of emerging contaminants from EuropeanWWTPs. Duration: 36 months, from september-2016 to august-2019. Total budget: 1.783.824 € (co-financed by European Commission).

Page 3: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.org

Specific goals To demonstrate that the combination of technologies is able to remove priority

substances and emerging contaminants (ECs), reaching: concentrations below the Directive 2013/39/UE threshold of chlorpyrifos, trifluralin, DEHP and 4-t-octylphenol, concentrations in a 99% of their original concentration of :

ECs included in the 1st watch list of DIRECTIVE 2013/39/UE: diclofenac, 17-a-ethinylestradiol and 17-b-estradiol, Other pharmaceutical pollutants: carbamazepine, ibuprofen, fluoxetine, chloramphenicol and estrone.

To design, construct and set-up a mobile DEMO plant able to reduce the listed ECs. To evaluate the occurrence of ECs in Europe. To assess the environmental and socio-economic impact of the project. To study the transferability of the project results to other European places with a

similar situation regarding ECs.

Page 4: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.org

Pilot plant locationBenidorm

(Alicante, Spain)

Benidorm is a popular tourist destination in Spain, whose population fluctuates considerably especially during Christmas, Easter and summer seasons. High presence of elderly population. Discharge of pharmaceutical products in wastewater.

Benidorm Wastewater Treatment Plant (BWWTP) (source: EPSAR)

Page 5: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

B1: Characterization of water samples GOAL: To quantify the pre-selected pollutants present at the inlet/output of BWWTP. To study the seasonal variability of the concentration of ECs in the wastewater

received by BWWTP.

METHODOLOGY Annual analytical campaign of the influent and effluent of BWWTP (54

samples from the influent and effluent) from Nov. 2016 to Dec. 2017. Analytical techniques: GC-MS/MS and HPCL-MS/MS

Priority substances Directive 2013/39/EU

1st Watch List 2013/39/EU

Other ECs

− DEHP− Chlorpyrifos− 4-t-OP

− Diclofenac− 17-a-ethinylestradiol− 17-b-estradiol

− Estrone− Chloramphenicol− Carbamazepine− Fluoxetine− Ibuprofen

CON

TAM

INAN

TS

− Trifluralin− Isoproturon− Diuron

− Erythromycin

− Sulfomethoxazole− Ketoprofen− AMPA− Glyphosate− Estriol

www.life-empore.org

Seasonal variability

Page 6: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.org

B2& B3.Design, implementation and set up Design: Hydraulic capacity: ∼ 5-5.5 m3·h-1 of secondary effluent from BWWTP Mobile/versatile format of the DEMO plant.

Conceptual scheme:

Page 7: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

Centrifugal pump

The clarifier wall was perforated to obtain thewater take

Pilot plantSecondary clarifier

Electrical connection of the DEMO plantto the electric archet.

www.life-empore.orgLocation

Page 8: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

Company Copersa S.A.Model Odismatic 851D02M-P Size 110 microns (140 mesh)Mesh area 850 cm2

Material Stainless steel meshDisposal Vertical

www.life-empore.org1st level

F-101: Cristal filter

Company HidrowaterModel FCR-779.

Material PRFVEffective filtration 3-5 µm

Cristal filler 500 kgDisposal Vertical

Company DowMembranes SFP 2660Número de membranas

3 modules in parallel

Type of membrane Hollow fiberFiltration / backwashcycles

25 min. / 3 min.

Pore size 0.03 µmSpecific surface 99 m2 (33 m2 each unit)

Material polyvinylidene fluoride(PVDF)

F-103: Ultrafiltration

A-101: UV lamp Company Aguas del Mare

NostrumModel AMN-550Nº lamps 2UV dosistransmittance99%

400 J/ m2

Material AISI 304

PREFILTRATION ULTRAFILTRATION

Page 9: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.org2nd level: a) Reverse osmosis

REVERSE OSMOSIS CARBON FILTER

Company DowMembrane BW30 4040Nº membranes 24

Type of membrane Spiral

Pressure tubes Pro-4-300-EP-4 Arisawa1st stage 16 membranes – 4 tubes

2 nd stage 8 membranes – 2 tubes

Pressure 10-12 bar

Conversion: 70% 1 pass and 2 stages

Company Aguas del Mare NostrumModelo DC-CLACK-200

Type of carbono Coconut shellFiller 100 kg

Disposal Vertical

RO permeate

3.5 m3/h

F-203Carbon filter

Page 10: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.org2nd level: b) AOPs

ADVANCED OXIDATION PROCESSES

Treatments:• O3

• O3+UV• O3+H2O2

• UV+H202

A-201: O3 generador A-202 / A-203.

Lámparas UV

Page 11: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.org3rd level: EAOPs

ELECTROCHEMICAL ADVANCED OXIDATION PROCESSES

Treatments:• Electrochemical

reactors• Electrochemical

reactors + UV

A-201: O3 generador

C-201y

C-202:Reactores

A-202 / A-203.Lámparas UV

RO / UFconcentrates

1.5 m3/h

C-301 and C-302:Electrochemical reactors

A-301: Ultraviolet lamp

2 reactors working in parallel• 5 electrodes anode (BDD)• 5 electrodes cathode (steel)

Page 12: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.orgPlant control SCADA

Page 13: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

Monitoring: weekly samples A) Concentration of each contaminant (indicators 1.3-01 to 1.3-20)

B) Canadian Water Quality Index (CWQI) considering the concentrations of ECsas variables and a modification named WQIEC that penalizes according to thenature of the ECs (indicator 1.3-21).

Benchmarks: Maximum Allowable Concentration (MAC) Directive 2013/39/EUfor priority substances; b) ECs: 2 x LOQ

N variables Water Quality ECs Classification

20 CWQI 28.3 PoorWQIEC 27.9 Poor

N variables Water Quality ECs Classification

20 CWQI 42.4 PoorWQIEC 39.7 Poor

SECONDARY EFFLUENT(54 samples)

INLET BWWTP(54 samples)

www.life-empore.org

C1. Monitoring of the impact of ECs removal

CWQI = 100−𝐅𝐅𝟏𝟏𝟐𝟐+𝐅𝐅𝟐𝟐

𝟐𝟐+𝐅𝐅𝟑𝟑𝟐𝟐

𝟏𝟏.𝟕𝟕𝟑𝟑𝟐𝟐(scale 0-100, 100 ideal)

Presence of priority substances and ECsin the secondary effluent.

Solution: EMPORE methodology

Seasonal variability

RESULTS B1: INFLUENT and SECONDARY EFFLUENT of BWWTPWeekly values of ECs concentration from Nov. 2016 to Dec. 2017 provided by LTL.

Page 14: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

Monitoring: weekly samples C) Canadian Water Quality Index considering general parameters

(indicator 1.3-22)

Parameters: total suspended solids (SS), conductivity, turbidity and pH.

Benchmarks: conductivity = 2500 µS·cm-1 at 20 ºC; pH = 6.5 – 9.5; SS =10 mg·L-1; and turbidity = 5 NTU.

RESULTS B1 : SECONDARY EFFLUENT of BWWTPMonthly values of each parameter from 2016 to 2017 provided by EPSAR:

www.life-empore.org

C1. Monitoring of the impact of ECs removal Poor-marginal quality.

Solution: EMPORE methodology

• 2016

pH (7.45 ± 0.15)

conductivity (3042 ± 245 µS·cm-1)

turbidity (8.22 ± 3.21 NTU)

SS (10.48 ± 8.84 mg·L-1)

Period N samples

N variables CWQI Classification

1st quarter 2016 4 4 47.0 Marginal2nd quarter 2016 4 4 38.6 Poor3rd quarter 2016 4 4 36.1 Poor1st quarter 2017 3 4 54.9 Marginal1st quarter 2017 3 4 54.2 Marginal3rd quarter 2017 4 4 56.6 Marginal

• 2017

pH (7.82 ± 0.14)

conductivity (2913 ± 178 µS·cm-1)

turbidity (2.40 ± 1.01 NTU)

SS (13.44 ± 5.64 mg·L-1)

Page 15: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

www.life-empore.org

Indicator Description Information obtained12.1.1 Number of entrances in the website

Interest aroused by the project12.1.2

Register of the number of events/exhibitions in which the

members of the Project have been invited to promote the technologies

proposed in the plant

12.1.3Survey about the acceptation of the

water used for irrigationSocial acceptation of

treated water

13.1Networking and other professional

training or educationDissemination of EMPORE results

15.5Incorporation of the proposed

technologies in advanced tertiary treatments for removal of ECs

Incorporation of the proposed technologies in public or private

companies.

16.1Tendencies change about the

availability of treated water free of ECs for reuse

Production of water free of ECs

15.1

Running cost/operating costs during the project and expected in case of

continuation/replication/transfer after the project period

Costs

C2. Monitoring the socio-economic impactIndicators for action C2 in “LIFE EMPORE INDICATOR LIST”.

Page 16: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

B4: Demonstration period. First results Demonstration: 1 year (starting date: July 2018)

www.life-empore.org

Water Quality: indicator 1.3-21

𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =𝑃𝑃𝑃𝑃𝑅𝑅𝑃𝑃𝑃𝑃𝑃𝑃𝑅𝑅𝑅𝑅𝑅𝑅𝑃𝑃 𝑅𝑅𝑜𝑜 𝑤𝑤𝑅𝑅𝑅𝑅𝑤𝑤𝑃𝑃 𝑜𝑜𝑃𝑃𝑤𝑤𝑤𝑤 𝑅𝑅𝑜𝑜 𝐸𝐸𝐸𝐸𝐸𝐸 𝑜𝑜𝑅𝑅𝑃𝑃 𝑃𝑃𝑤𝑤𝑃𝑃𝐸𝐸𝑤𝑤

𝑇𝑇𝑅𝑅𝑅𝑅𝑅𝑅𝑇𝑇 𝑤𝑤𝑅𝑅𝑅𝑅𝑤𝑤𝑃𝑃 𝑅𝑅𝑃𝑃𝑤𝑤𝑅𝑅𝑅𝑅𝑤𝑤𝑃𝑃 𝑅𝑅𝑃𝑃 𝑅𝑅𝑡𝑤𝑤 𝑝𝑝𝑇𝑇𝑅𝑅𝑃𝑃𝑅𝑅

Effluent with high quality: line permeates. After 2nd level, ECs removal efficiencies > 99%

(except for glyphosate & AMPA ∼ 97%).

Page 17: FIRST RESULTS OF PROJECT EMPORE -LIFE15 “DEVELOPMENT …congresoaedyr.com/wp-content/uploads/2018/11/Ponencias/01-MARTES_23-S1... · Other pharmaceutical pollutants: carbamazepine,

Partners.Duration.

Budget.

EMPORE (ref. LIFE15 ENV/ES/000598) is co-financied by LIFE+2015 Call. The LIFE Programme is the EU’s funding instrument for the environment and climate action.

EU financialcontribution 1.030.407 €

Financial contribution.

www.life-empore.org


Recommended